Alendronate for the Treatment of Osteoporosis in Men
Eric Orwoll, Mark P. Ettinger, Stuart Weiss, Paul D. Miller, David L. Kendler, John Graham, Silvano Adami, Kurt Weber, R Lorenc, Peter Pietschmann, Kristel Vandormael, Antonio Lombardi
New England Journal of Medicine, 2000
Abstract
This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).
- Growth hormone binding protein in the rat: effects of gonadal steroids. 1993
- Exogenous Glucocorticoids and a High-Fat Diet Cause Severe Hyperglycemia and Hyperinsulinemia and Limit Islet Glucose Responsiveness in Young Male Sprague-Dawley Rats 2013
- Osteoporosis: diagnosis and management 1998
- The Effect of Fasting on Tissue Cyclic cAMP and Plasma Glucagon in the Obese Hyperglycemic Mouse 1975
- Modulation of Adipoinsular Axis in Prediabetic Zucker Diabetic Fatty Rats by Diazoxide 2004
- Prevalence of low femoral bone density in older U.S. women from NHANES III 1995
- The prevalence of vertebral deformity in European men and women: The european vertebral osteoporosis study 1996
- Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation <i>in vitro</i> 1999
- Bone Density and Fracture Risk in Men 1998
- Effects of Alendronate on Bone Density in Men with Primary and Secondary Osteoporosis 2000